Results 131 to 140 of about 118,257 (252)

Longitudinal Trends in HIV-1 Subtypes and Drug Resistance in Children from Argentina over a 15-Year Period (2006-2021)

Revista de Investigación Clínica
Background: Human immunodeficiency virus (HIV) drug resistance is a major cause of treatment failure in children and adolescents infected with the virus.
Natalia J. López, Solange Arazi-Caillaud, Rosa M. Bologna, Andrea M. Mangano, Cristina P. Aulicino   +4 more
doaj   +1 more source

HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect. [PDF]

Antiviral Res, 2022
Foo CS, Abdelnabi R, Kaptein SJF, Zhang X, Ter Horst S, Mols R, Delang L, Rocha-Pereira J, Coelmont L, Leyssen P, Dallmeier K, Vergote V, Heylen E, Vangeel L, Chatterjee AK, Annaert PP, Augustijns PF, De Jonghe S, Jochmans D, Gouwy M, Cambier S, Vandooren J, Proost P, van Laer C, Weynand B, Neyts J.   +25 more
europepmc   +1 more source

The impact of accumulating immune adaptation in circulating strains of HIV‐1

HIV Medicine, EarlyView.
Abstract Background Mutations in human immunodeficiency virus type 1 (HIV‐1) enable the virus to evade recognition and killing by human leucocyte antigen (HLA)‐restricted T cells. These viral adaptations are specific to the HLA type of individuals and are therefore evident as HLA allele‐HIV sequence associations at the population level. Most studies of
Marwah Al‐kaabi, Alison Castley, Pooja Deshpande, Abha Chopra, David Nolan, Simon Mallal, Mina John, Silvana Gaudieri   +7 more
wiley   +1 more source

Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus. [PDF]

J Mol Graph Model, 2021
Prashantha CN, Gouthami K, Lavanya L, Bhavanam S, Jakhar A, Shakthiraju RG, Suraj V, Sahana KV, Sujana HS, Guruprasad NM, Ramachandra R.   +10 more
europepmc   +1 more source

Real‐world use of second‐generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS‐CO3‐AquiVIH‐NA cohort

HIV Medicine, EarlyView.
Abstract Objectives To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods People living with HIV from the prospective ANRS‐CO3‐
O. Leleux, A. Peyrouny‐Mazeau, A. Perrier, M. Hessamfar, G. Le Moal, D. Neau, L. Alleman, C. Cazanave, E. Lazaro, P. Duffau, A. Riché, Y. Gérard, G. Barrière, S. Reigadas, M.‐A. Vandenhende, F. Bonnet   +15 more
wiley   +1 more source

Molecular dynamics simulation of docking structures of SARS-CoV-2 main protease and HIV protease inhibitors. [PDF]

J Mol Struct, 2021
Cardoso WB, Mendanha SA.
europepmc   +1 more source

Postoperative Pain After Endodontic Treatment in HIV‐Positive Patients Under HAART: A Prospective Observational Cohort Study

International Endodontic Journal, EarlyView.
ABSTRACT Aim To compare post‐operative pain following root canal treatment (RCT) in HIV‐positive patients receiving highly active antiretroviral therapy (HAART) and HIV‐negative patients and to assess the influence of systemic condition on endodontic pain.
Marcos Felipe Iparraguirre Nuñovero, Marco Antonio Hungaro Duarte, Luciana Reis Azevedo Alanis, Bruno Cavalini Cavenago, Ulisses Xavier da Silva Neto, Everdan Carneiro   +5 more
wiley   +1 more source

Inflammatory and Immunological Basis of Periodontal Diseases

Journal of Periodontal Research, EarlyView.
The periodontal lesion emerges as an evolving immunological battlefield, where host–microbiome interactions, dysregulated immune responses, fragile resolution mechanisms, and inflammophilic dysbiosis converge to shift the balance from homeostasis to unrestrained tissue destruction.
Giacomo Baima, Marion Arce, Mario Romandini, Thomas Van Dyke   +3 more
wiley   +1 more source

Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19. [PDF]

Eur J Clin Pharmacol, 2021
von Hentig N.
europepmc   +1 more source

The Multifaceted Legacy of Thalidomide: Chemistry and Biology Driving Modern Drug Design

ChemMedChem, Volume 21, Issue 7, 14 April 2026.
Thalidomide serves as a molecular nexus linking chemistry and biology: advances in synthesis and structural understanding enable protein degradation technologies, while its immunomodulatory activity underpins anti‐inflammatory and anticancer therapies.
Konstantina Nikovia, Michael Kapsalis, Michael Georgoulakis, Athanasios Panousis, Constantinos G. Neochoritis   +4 more
wiley   +1 more source